Introduction
For all the advances in endoscopic retrograde cholangiopancreatography (ERCP), benign
pancreaticobiliary strictures refractory to conventional endoscopic therapies such
as dilation and stenting remain challenging to manage. These refractory strictures
can result in abdominal pain, jaundice, pancreatitis, and cholangitis. Furthermore,
obstructing strictures precluding catheter advancement may not be amenable to standard
endoscopic techniques. Within the chronic pancreatitis population, nearly 20 % of
patients will develop main pancreatic duct (PD) strictures [1]. If symptomatic, treatment recommendations typically include pancreatic sphincterotomy
in combination with dilation and stenting, preferably with a 10 Fr stent [2]. Refractory strictures are classically defined as those that persist or relapse
1 year after placement of a single stent, although in our practice, we often perform
multiple side-by-side stenting across symptomatic strictures prior to considering
them to be refractory [2]. Endoscopic measures for these refractory strictures entail placement of multiple
side-by-side plastic stents or covered metal stents. Long-term data regarding multiple
plastic stent placement, however, demonstrate recurrence of pain in 25 % of patients
after stent removal [3]. Within this context, novel therapies are needed to treat refractory strictures
in an effort to facilitate earlier resolution of strictures. This may permit a reduction
in stent-associated stricture while avoiding repeated procedures and potentially pancreatic
surgery for a benign condition that has multifactorial mechanisms for pain [4].
Lasers have been used for ablation purposes in urological indications, and preliminary
studies in the biliary tract have demonstrated safety, therefore, this therapy potentially
represents a novel endoscopic technique for dissection and ablation [5]
[6]
[7]
[8]. The aim of this study was to evaluate the safety and efficacy of laser dissection/ablation
for refractory strictures in the pancreas and biliary tract.
Patients and methods
This study was approved by the Colorado Multiple Institutional Review Board.
Patients
This retrospectively identified case series included patients treated with laser dissection/ablation
from February 2017 to September 2019 at a single tertiary medical center. All patients
had non-malignant strictures with symptoms including abdominal pain, jaundice, and
recurrent pancreatitis refractory to prior treatment with dilation and stenting. In
regards to selection of patients for this treatment, those with strictures with concentric
ring/band fibrosis or mucosal hyperplastic changes were considered amenable to laser
dissection. Patients with extrinsic strictures or non-obstructive fibrotic bands or
rings were not considered ideal candidates for laser therapy. Three patients had been
previously described in case reports [5]
[6]. All procedures were performed by a single endoscopist (RJS).
Technique
ERCP was performed using standard techniques with a side-viewing duodenoscope (Olympus,
Center Valley, Pennsylvania, United States) in patients with normal anatomy or a pediatric
colonoscope (Olympus) in a single patient status post-Whipple procedure. After deep
cannulation, a 200- to 272-µm laser fiber (International Medical Lasers, Tualatin,
Oregon, United States) was advanced into the desired duct. For intraductal strictures,
direct visualization using a 10.5 Fr single-operator cholangiopancreatoscope (SpyGlass
DS or DS2, Boston Scientific, Marlborough, Massachusetts, United States) guided placement
of the fiber to the stricture location. Holmium (Litho, Quanta System, Italy) or thulium
(Cyber TM, Quanta System, Italy) laser was applied ([Fig. 1]) under saline immersion at the discretion of the endoscopist using lower power settings
than lithotripsy (frequency of 8–10 Hz, energy of 0.5 Joules, and power of 5–20 Watts).
Holmium enables lithotripsy of main pancreatic duct (PD) stones and was used simultaneously
when stricture dissection was required to improve access to impacted stones upstream
of PD strictures [9]. Compared to holmium, thulium provides a continuous wave that has a shallower depth
of penetration and may be beneficial in dissection or ablation [10]. For stricture dissection, gentle strokes of the laser fiber using a “cut” setting
from a distal to proximal approach was applied in three quadrants until improved luminal
patency permitted advancement of the cholangiopancreatoscope followed by balloon dilation
and therapeutic stenting in all patients ([Video 1]). For ablation, which was used to treatment an intraductal papillary mucinous neoplasm
(IPMN), shorter strokes using both “cut” and “coagulation” were performed until obliteration
of the tissue to the level of the mucosal surface was achieved.
Fig. 1 Laser dissection of a pancreatic duct stricture (top panels) with improvement seen
on pancreatogram (bottom panels).
Video 1 Laser dissection of a pancreatic duct stricture.
Outcomes
Initial stricture measurements by pancreatography, after the previously placed stent
had been removed and prior to CPL, used the diameter of the duodenoscope as a reference
point. Immediate technical success was defined as the ability to traverse the stricture
with the cholangiopancreatoscope after dissection or obliteration of the lesion and
short-term technical success for strictures was defined as greater than 90 % resolution
of the treated stenosis as seen on a subsequent pancreatography session compared to
pre-treatment pancreatography. Adverse events (AEs) were defined in accordance to
ERCP-related adverse events as outlined by the American Society for Gastrointestinal
Endoscopy (ASGE) [11].
Results
A total of 11 patients (90.9 % female, mean age of 58 ± 12.2 years) underwent laser
dissection/ablation ([Table 1]). Nine patients had refractory PD strictures, one of whom had a concomitant pancreaticojejunostomy
anastomotic stricture. Three of these patients had two strictures along the PD treated
with laser dissection. One patient had an inoperable intraductal papillary mucinous
neoplasm (IPMN) ([Fig. 2]) and recurrent episodes of pancreatitis despite therapeutic PD stenting and one
patient had a refractory, symptomatic common hepatic duct/hilar stricture that did
not improve with multiple side-by-side stents. Patients had a mean of 3.6 ERCPs prior
to CPL with dilation/stenting and a mean total stent(s) outer diameter of 14.2 Fr
for PD strictures.
Table 1
Patient characteristics (N = 11).
Variable
|
Mean (SD) or N (%)
|
Age
|
58 (12.2)
|
Female sex
|
10 (90.9 %)
|
Indication
|
|
8 (72.7 %)
|
|
1 (9.1 %)
|
|
1 (9.1 %)
|
|
1 (9.1 %)
|
|
3.6 (2.6)
|
Prior stricture dilations
|
9 (81.8 %)
|
|
6 (1)
|
Prior stenting
|
10 (90.9 %)
|
|
14.2 (10.9)
|
Smoker
|
5 (45.5 %)
|
History of alcohol abuse
|
5 (45.5 %)
|
Disease duration (years)
|
5.5 (6.7)
|
Follow-up time (months)
|
12.1 (11.1)
|
Fig. 2 Intraductal papillary mucinous neoplasm (left) and after laser ablation (right).
In all, 17 (median 1, range 1–3) sessions of laser therapy were performed with holmium
used most frequently (73.3 %) and a median energy delivered of 8.5 kJ ([Table 2]). The cholangiopancreatoscope was unable to traverse the strictures prior to laser
therapy. After laser therapy, immediate technical success (e. g. ability to traverse
the stricture with the cholangiopancreatoscope) ([Fig. 3]) was 94.1 % with the one failure being in a post-Whipple patient where laser dissection
was successful in opening an anastomotic stricture that reoccurred despite prior needle-knife/balloon
dilation stricturoplasty, but failed in improving lumen patency of a stricture in
the body of the pancreas. In the case of IPMN ablation, the pancreatoscope was immediately
able to be advanced past the ablated IPMN and subsequent ERCP with pancreatoscopy
revealed minimal residual tumor with significantly less mucin identified. The short-term
technical success (> 90 % resolution of the treated stenosis on subsequent ERCP) rate
was 88.2 % (15/17 strictures) where in addition to the aforementioned post-Whipple
patient, one patient with chronic pancreatitis secondary to alcohol did not have improvement
in a stricture in the head of the pancreas despite two sessions of holmium therapy.
Laser therapy also permitted access to downstream PD stones for concomitant lithotripsy
([Fig. 4]) in seven patients (63.6 %) in whom stricture dilation alone due to balloon breakage
or difficult fibrosis was insufficient. The patient with IPMN has had no further episodes
of pancreatitis at 39 months since index laser ablation and continues to receive pancreatic
duct stent exchanges at 6-month intervals to prevent pancreatic duct obstruction from
gradual mucin accumulation. After laser therapy, patients underwent a mean of 2.7
ERCPs with stenting typically performed after pancreatoscopy-guided lithotripsy until
complete clearance of stones was achieved. In patients who received further stenting
on subsequent ERCP, stents with a larger diameter (mean increase of 3.9 Fr) were able
to be placed. During a mean follow-up period of 12.1(± 11.1) months, there have been
no stricture recurrences.
Table 2
Laser treatment details.
Patient
|
Location of laser treatment
|
Disease etiology
|
No. laser sessions
|
Type of laser
|
Total energy (Kilojoules)
|
Immediate technical success
|
Short-term technical success
|
Adverse events
|
1
|
1. Pancreaticojejunostomy Anastomosis
2. PD body stricture
|
Ampullary cancer s/p Whipple
|
2 (over 2 months)
|
1.Holmium
2.Thulium
|
1. 0.19
2. 1.69
|
1.Yes
2. No
|
1.Yes
2. No
|
None
|
2
|
PD body stricture
|
Idiopathic chronic pancreatitis
|
1
|
Holmium
|
7.82
|
Yes
|
Yes
|
None
|
3
|
Common hepatic duct
|
Cholecystectomy injury
|
1
|
Thulium
|
1.61
|
Yes
|
Yes
|
None
|
4
|
PD head stricture
|
Alcohol/smoking chronic calcific pancreatitis
|
1
|
Holmium
|
19.82
|
Yes
|
Yes
|
None
|
5
|
PD head stricture
|
Alcoholic chronic pancreatitis
|
2
|
Holmium (twice)
|
1. 25.56
2. 12.6
|
Yes
|
No
|
None
|
6
|
PD head stricture
|
Idiopathic chronic pancreatitis
|
1
|
Holmium
|
3.64
|
Yes
|
Yes
|
None
|
7
|
PD head stricture
|
Alcohol/smoking chronic calcific pancreatitis
|
1
|
Holmium
|
18.16
|
Yes
|
Yes
|
None
|
8
|
1. PD head stricture
2. PD body stricture
|
Idiopathic chronic pancreatitis
|
1
|
1. Thulium
2. Thulium
|
2.31
|
1. Yes
2. Yes
|
1.Yes
2. Yes
|
None
|
9
|
1. PD body stricture
2. PD genu stricture
|
Intraductal papillary mucinous neoplasm
|
3 (over 39 months)
|
1. Holmium
2. Holmium
3. Thulium
|
1. 0.33
2. 0.71
3. 0.28
|
1. Yes
2. Yes
|
1. Yes
2. Yes
|
None
|
10
|
PD body stricture
|
Alcohol/smoking chronic calcific pancreatitis
|
1
|
Holmium
|
9.25
|
Yes
|
Yes
|
Yes (pneumonia)
|
11
|
PD head stricture
|
Alcohol/smoking chronic calcific pancreatitis
|
3
|
1. Holmium
2. Holmium
3. Holmium
|
1. 16.26
2. 17.62
3. 9.90
|
Yes
|
Yes
|
None
|
PD, pancreatic duct.
Fig. 3 Common hepatic duct/hilar stricture before (left) and after (right) laser dissection.
Fig. 4 Stricture in the pancreatic duct (above) treated with laser dissection and permitted
access to obstructing stone for lithotripsy (below).
In terms of AEs, one episode of likely anesthesia-related pneumonia occurred and there
were no endoscopy-related AEs such as pancreatitis or perforation.
Discussion
Refractory pancreatic and biliary strictures and inoperable neoplasms such as IPMNs
can pose significant problems such as persistent pain, stent-dependency, or recurrent
bouts of pancreatitis. While typically treated with numerous sessions of multiple
plastic or fully-covered metal stents, these therapies may not provide an effective
long-term solution and cause significant burden in the number of repeat procedures
for these patients that may often render patients “stent-dependent.” Given the morbidity
of surgery and the multi-factorial mechanisms of pain of patients suffering from chronic
pancreatitis, salvage endoscopic therapies such as laser dissection/ablation may provide
an alternative, effective, and durable treatment modality.
In this case series, we demonstrate the potential efficacy of holmium or thulium laser
therapy in treating refractory strictures. With regard to pancreatic duct strictures,
the use of fully-covered metal stents may provide an effective long-term option, but
in addition to cost, are subject to serious AEs including stent migration, stent-induced
and non-traversable de novo strictures, and obstruction of the PD side branches, which
may result in pancreatic sepsis [12]
[13]. Furthermore, catheter access across the stenosis is required for dilation and placement
of plastic or metal stents. With laser dissection, the stenosis can be treated with
guidewire traversal of the stricture alone. In addition, in patients with symptomatic
PD stones, laser dissection of downstream stenoses can improve access and allow for
immediate lithotripsy of impacted stones, providing an efficient means of endoscopic
therapy. Lastly, effective laser dissection may reduce the number of additional procedures
associated with stent exchanges/upsizing while also reducing risk of development of
stent-associated strictures.
Salvage methods for non-operable IPMN include radiofrequency ablation (RFA) or alcohol
ablation performed via ERCP or under endosonographic guidance [14]
[15]. Baughman et al detailed use of laser fulguration with a holmium laser fiber within
a ureteroscope through a percutaneous biliary drain in a single patient with a biliary
IPMN, but application of laser ablation endoscopically in the pancreatic duct under
direct visualization as described in this study offers another treatment modality
for IPMN [16]. While surgical resection remains the treatment of choice for main-duct IPMNs, further
studies examining laser ablation are needed in non-surgical symptomatic patients.
Limitations of this study include its retrospective nature and lack of long-term follow-up
data. In addition, as one expert endoscopist performed all laser dissection/ablation
with patients selected at the discretion of the endoscopist, the generalizability
remains limited at this time.
Conclusion
In summary, laser dissection/ablation is a feasible salvage therapy for treatment
of refractory pancreaticobiliary strictures. To improve intraductal lithotripsy targeting
of impacted stones with associated tight downstream strictures, dissection may be
beneficial. Further, patients who have already had dilation and therapeutic stenting
without appreciable improvement by pancreatography or in strictures where only the
guidewire is able to traverse, may potentially benefit from this technique. We caution,
however, that using this technique in patients with complete obstruction and inability
to traverse the stricture with the guidewire as laser dissection may result in ductal
perforation. If a smaller-diameter .025-inch wire is used to traverse the stenosis,
a laser fiber may be passed in parallel through the cholangioscope working channel
and serve as a “safety wire” to assure bridging the stenosis for stenting in case
of transmural ductal injury. Larger multicenter studies with long-term follow-up,
however, are required to demonstrate the safety, efficacy, and durability of this
novel technique. In addition, given the cost associated with use of both the cholangioscopy
and laser systems, randomized studies comparing this technique with other modalities
are warranted to address cost-effectiveness but would need to be weighed with surgical
alternatives and associated morbidity and mortality. Finally, while this technique
should only be performed in expert hands with significant experience not only in therapeutic
pancreatic ERCP but also with cholangiopancreatoscopy, laser therapy adds to the arsenal
of tools available to the endoscopist.